1-4 of 4
Jiahui Li
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Efficacy and safety of luspatercept (LUSPA) versus placebo (PBO) in patients (pts) with myelofibrosis (MF) on Janus kinase 2 inhibitor (JAKi) therapy who require red blood cell transfusions (RBCT): primary analysis of the Phase 3 randomized INDEPENDENCE trial

Free
Francesco Passamonti, Jean-Jacques Kiladjian, John Mascarenhas, Claire Harrison, Ruben Mesa, Elisabetta Abruzzese, Harinder Gill, Stefan Wickenhauser, Je-Hwan Lee, Zhijian Xiao, Fabrizio Pane, Suning Chen, Chunting Zhao, Argiris Symeonidis, Fabian Sanabria, Julie Vienne Buerki, Ana Carolina Giuseppi, Jiahui Li, Patricia Martin-Regueira, Haifa Kathrin Al-Ali
Journal: Blood
Blood (2025) 146 (Supplement 1): 907.
https://doi.org/10.1182/blood-2025-907
Published: 2025
Journal Articles

Development of Next Generation Antibody-Polymer-Drug Conjugates for Treatment of Multiple Myeloma

Free
Jiahui Li, Michael Thomas Gambles, Shannuo Li, Jindřich Kopeček, Douglas Sborov, Jiyuan Yang
Journal: Blood
Blood (2023) 142 (Supplement 1): 3308.
https://doi.org/10.1182/blood-2023-186661
Published: 2023
Journal Articles

Efficacy and Safety of Luspatercept Versus Epoetin Alfa in Erythropoiesis-Stimulating Agent (ESA)-Naive Patients (Pts) with Transfusion-Dependent (TD) Lower-Risk Myelodysplastic Syndromes (LR-MDS): Full Analysis of the COMMANDS Trial

Free
Guillermo Garcia-Manero, Uwe Platzbecker, Valeria Santini, Amer M. Zeidan, Pierre Fenaux, Rami S. Komrokji, Jake Shortt, David Valcarcel, Anna Jonasova, Sophie Dimicoli-Salazar, Ing Soo Tiong, Chien-Chin Lin, Jiahui Li, Jennie Zhang, Ana Carolina Giuseppi, Sandra Kreitz, Veronika Pozharskaya, Karen L. Keeperman, Shelonitda Rose, Thomas Prebet, Andrius Degulys, Stefania Paolini, Thomas Cluzeau, Matteo Giovanni Della Porta
Journal: Blood
Blood (2023) 142 (Supplement 1): 193.
https://doi.org/10.1182/blood-2023-178596
Published: 2023
Journal Articles

MAGNIFY: Phase IIIb Randomized Study of Lenalidomide Plus Rituximab (R 2 ) Followed By Lenalidomide Vs. Rituximab Maintenance in Subjects with Relapsed/Refractory Follicular, Marginal Zone, or Mantle Cell Lymphoma

Free
David J. Andorsky, MD, Abdulraheem Yacoub, MD, Jacob D. Bitran, MD, Jason Melear, MD, Heather D. Brooks, MD BS, BA, Kenneth A. Foon, MD, Syed Rizvi, MD, Mary Llorente, Jiahui Li, PhD, Jeff P. Sharman, MD
Journal: Blood
Blood (2016) 128 (22): 1798.
https://doi.org/10.1182/blood.V128.22.1798.1798
Published: 2016